文献速递心脏核医学

68Ga-喷替沙福PET对动脉粥样硬化斑块趋化因子受体CXCR4表达的临床分子成像:与心血管危险因素及钙化斑块负荷的相关性

Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden.
PubMed 文献 · J Nucl Med · 2017-08-03

回顾性分析51例因非心血管指征行68Ga-喷替沙福PET/CT患者的动脉壁示踪剂摄取,发现51例(100%)均见局灶性摄取,共1411处,且摄取与钙化斑块负荷及年龄、高血压、高胆固醇血症、吸烟史、既往心血管事件等危险因素显著相关,危险因素数目越多摄取越广泛且信号越强。

要点

  • 51例(100%)患者动脉壁见局灶性68Ga-喷替沙福摄取,共1411处。
  • 摄取与钙化斑块负荷及多项心血管危险因素显著相关。
  • 危险因素数目增加时摄取 prevalence(P<0.0001)与信号强度(P=0.009)均增加。

核心结论

  • 68Ga-喷替沙福PET/CT适用于对动脉粥样硬化动脉壁CXCR4表达进行无创、高特异性PET成像。
  • 动脉壁68Ga-喷替沙福摄取与动脉粥样硬化替代标志物显著相关,并与心血管危险因素的存在相关。
  • 高危特征患者的68Ga-喷替沙福信号更高,可能有助于识别易损斑块。

研究设计与样本

  • 回顾性分析51例因非心血管指征行68Ga-喷替沙福PET/CT的患者。
  • 对主要动脉血管壁示踪剂摄取进行定性及半定量分析,半定量采用经血池校正的靶/本底比值。
  • 将示踪剂摄取与钙化斑块负荷及心血管危险因素进行比较。

主要发现

  • 51例(100%)患者共1411处见局灶性动脉68Ga-喷替沙福摄取。
  • 68Ga-喷替沙福摄取与钙化斑块负荷显著相关(P<0.0001)。
  • 摄取与年龄(P<0.0001)、动脉性高血压(P<0.0001)、高胆固醇血症(P=0.0005)、吸烟史(P=0.01)及既往心血管事件(P=0.0004)显著相关。
  • 随着危险因素数目增加,68Ga-喷替沙福摄取的患病率(P<0.0001)与信号强度(P=0.009)均增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The CXC-motif chemokine receptor 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types in cardiovascular diseases such as atherosclerosis and arterial wall injury. The aim of this study was to assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of 68Ga-pentixafor, a specific CXCR4 ligand for PET. Methods: The data for 51 patients who underwent 68Ga-pentixafor PET/CT for noncardiovascular indications were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed qualitatively and semiquantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with calcified plaque burden and cardiovascular risk factors. Results: Focal arterial uptake of 68Ga-pentixafor was seen at 1,411 sites in 51 (100%) of patients. 68Ga-pentixafor uptake was significantly associated with calcified plaque burden (P < 0.0001) and cardiovascular risk factors including age (P < 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P = 0.01), and prior cardiovascular events (P = 0.0004). Both the prevalence (P < 0.0001) and the signal intensity (P = 0.009) of 68Ga-pentixafor uptake increased as the number of risk factors increased. Conclusion:68Ga-pentixafor PET/CT is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic arterial wall. Arterial wall 68Ga-pentixafor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to the presence of cardiovascular risk factors. 68Ga-pentixafor signal is higher in patients with a high-risk profile and may hold promise for identification of vulnerable plaque.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Weiberg D, Thackeray JT, Daum G, et al. Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden. J Nucl Med. 2017. PMID: 28775206. doi:10.2967/jnumed.117.196485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。